Study | Gender(M/F) | Age | N | Treatment | Duration (weeks) | Outcomes |
---|---|---|---|---|---|---|
Rosenstock, et al. (2021) [17] | 56/59 | 53.6 ± 12.8 | 115 | Placebo | 40 | HbA1c,Weight,AE, SAE |
56/65 | 54.1 ± 11.9 | 121 | Tir 5mg |  |  | |
72/49 | 55.8 ± 10.4 | 121 | Tir 10mg |  |  | |
63/58 | 52.9 ± 12.3 | 121 | Tir 15mg |  |  | |
Frias, et al. (2020) [18] | 12/14 | 56.0 ± 10.13 | 26 | Placebo | 12 | HbA1c,Weight,AE, SAE |
16/13 | 55.5 ± 8.54 | 29 | Tir 15mg |  |  | |
Frias, et al. (2018) [19] | 29/22 | 56.6 ± 8.9 | 51 | Placebo | 26 | HbA1c,Weight,AE, SAE |
34/21 | 57.9 ± 8.2 | 55 | Tir 5mg |  |  | |
30/21 | 56.5 ± 9.9 | 51 | Tir 10mg |  |  | |
22/31 | 56.0 ± 7.6 | 53 | Tir 15mg |  |  | |
Heise, et al. (2022) [20] | 21/7 | 60.4 ± 7.6 | 28 | Placebo | 28 | Weight,AE, SAE |
31/14 | 61.1 ± 7.1 | 45 | Tir 15mg |  |  | |
Blonde, et al. (2020) [21] | 58/42 | 56.0 ± 9.9 | 100 | Placebo | 26 | HbA1c,Weight,AE, SAE |
125/78 | 54.7 ± 10.1 | 203 | Lir 1.8mg |  |  | |
Harder, et al. (2004) [22] | 1/11 | 60.1 ± 6.7 | 12 | Placebo | 8 | HbA1c,Weight |
11/10 | 59.9 ± 11.0 | 21 | Lir 0.6mg |  |  | |
Seino, et al. (2008) [23] | 29/17 | 57.5 ± 8.7 | 46 | Placebo | 14 | HbA1c,Weight |
28/17 | 60 ± 7.0 | 45 | Lir 0.6mg |  |  | |
Marre, et al. (2009) [24] | 54/60 | 54.7 ± 10.0 | 114 | Placebo | 26 | HbA1c,Weight, SAE |
126/107 | 55.7 ± 9.9 | 233 | Lir 0.6mg |  |  | |
102/126 | 57.7 ± 9.0 | 228 | Lir 1.2mg |  |  | |
124/110 | 55.6 ± 10.0 | 234 | Lir 1.8mg |  |  | |
Russell-Jones, et al. (2009) [25] | 56/59 | 57.5 ± 9.6 | 115 | Placebo | 26 | HbA1c,Weight,AE, SAE |
132/100 | 57.6 ± 9.5 | 232 | Lir 1.8mg |  |  | |
Yale, et al. (2017) [26] | 41/28 | 64.3 ± 7.76 | 69 | Placebo | 52 | HbA1c,Weight,AE, SAE |
37/37 | 64.3 ± 8.49 | 74 | Can 100mg |  |  | |
42/30 | 65.8 ± 7.88 | 72 | Can 300mg |  |  | |
Kadowaki, et al. (2017) [27] | 53/15 | 56.0 ± 9.5 | 68 | Placebo | 24 | HbA1c,Weight,AE, SAE |
54/16 | 58.4 ± 8.9 | 70 | Can 100mg |  |  | |
Inagaki, et al. (2013) [28] | 54/21 | 57.7 ± 11.0 | 75 | Placebo | 12 | HbA1c,Weight,SBP,DBP,AE, SAE |
52/22 | 57.7 ± 10.5 | 74 | Can 100mg |  |  | |
49/27 | 57.0 ± 10.7 | 76 | Can 200mg |  |  | |
55/20 | 57.1 ± 10.1 | 75 | Can 300mg |  |  | |
Inagaki, et al. (2014) [29] | 60/33 | 58.2 ± 11.0 | 93 | Placebo | 24 | HbA1c,Weight,SBP,DBP,AE, SAE |
60/33 | 58.4 ± 10.4 | 93 | Can 100mg |  |  | |
72/16 | 57.4 ± 11.1 | 88 | Can 200mg |  |  | |
Stenlof, et al. (2013) [30] | 88/104 | 55.7 ± 10.9 | 192 | Placebo | 26 | HbA1c,Weight,SBP,DBP,AE, SAE |
81/114 | 55.1 ± 10.8 | 195 | Can 100mg |  |  | |
89/108 | 55.3 ± 10.2 | 197 | Can 300mg |  |  | |
Ji, et al. (2019) [31] | 88/79 | 56.9 ± 9.0 | 167 | Placebo | 26 | HbA1c,Weight,SBP,DBP,AE, SAE |
95/65 | 56.1 ± 9.0 | 160 | Ert 5mg |  |  | |
98/71 | 56.3 ± 9.3 | 169 | Ert 15mg |  |  | |
Terra, et al. (2017) [32] | 82/71 | 56.1 ± 10.9 | 153 | Placebo | 26 | HbA1c,Weight,AE, SAE |
89/67 | 56.8 ± 11.4 | 156 | Ert 5mg |  |  | |
90/62 | 56.2 ± 10.8 | 152 | Ert 15mg |  |  | |
Rosenstock, et al. (2018) [44] | 98/111 | 56.5 ± 8.7 | 209 | Placebo | 26 | HbA1c,Weight,AE, SAE |
97/110 | 56.6 ± 8.1 | 207 | Ert 5mg |  |  | |
93/112 | 56.9 ± 9.4 | 205 | Ert 15mg |  |  | |
Dagogo-Jack S, et al. (2018) [33] | 100/53 | 58.3 ± 9.2 | 153 | Placebo | 52 | HbA1c,Weight,AE, SAE |
81/75 | 59.2 ± 9.3 | 156 | Ert 5mg |  |  | |
82/71 | 59.7 ± 8.6 | 153 | Ert 15mg |  |  | |
Kadowaki, et al. (2014) [34] | 80/29 | 58.7 ± 8.7 | 109 | Placebo | 12 | HbA1c,Weight,SBP,DBP,AE, SAE |
84/26 | 57.3 ± 11.2 | 110 | Emp 5mg |  |  | |
77/32 | 57.9 ± 9.4 | 109 | Emp 10mg |  |  | |
84/25 | 57.2 ± 9.7 | 109 | Emp 25mg |  |  | |
Søfteland, et al. (2017) [35] | 60/48 | 55.9 ± 9.7 | 108 | Placebo | 24 | HbA1c,Weight,AE, SAE |
66/43 | 54.3 ± 9.6 | 109 | Emp 10mg |  |  | |
71/39 | 55.4 ± 9.9 | 110 | Emp 25mg |  |  | |
Nishimura, et al. (2015) [36] | 17/4 | 60.7 ± 10.8 | 21 | Placebo | 4 | AE, SAE |
14/6 | 64.8 ± 5.9 | 20 | Emp 10mg |  |  | |
16/3 | 62.6 ± 7.8 | 19 | Emp 25mg |  |  | |
Ferrannini, et al. (2013) [37] | 45/37 | 58.0(28–80) | 82 | Placebo | 12 | HbA1c,Weight,AE |
46/35 | 59.0(37–78) | 81 | Emp 5mg |  |  | |
40/41 | 58.0(30–76) | 81 | Emp 10mg |  |  | |
41/41 | 57.0(30–79) | 82 | Emp 25mg |  |  | |
Roden, et al. (2013) [38] | 123/105 | 54.9 ± 10.9 | 228 | Placebo | 24 | HbA1c,Weight,SBP,DBP,AE, SAE |
142/82 | 56.2 ± 11.6 | 224 | Emp 10mg |  |  | |
145/79 | 53.8 ± 11.6 | 224 | Emp 25mg |  |  | |
Papadopoulou, et al. (2021) [39] | 21/21 | 60.6 ± 9.4 | 42 | Placebo | 12 | HbA1c,Weight |
23/20 | 61.7 ± 6.7 | 43 | Dap 10mg |  |  | |
Yang, et al. (2016) [40] | 86/59 | 53.5 ± 9.2 | 145 | Placebo | 24 | HbA1c,Weight,SBP,AE, SAE |
67/80 | 53.1 ± 9.1 | 147 | Dap 5mg |  |  | |
88/64 | 54.6 ± 9.5 | 152 | Dap 10mg |  |  | |
Bailey, et al. (2010) [41] | 76/67 | 53.7 ± 10.3 | 143 | Placebo | 24 | HbA1c,Weight,AE, SAE |
69/68 | 54.3 ± 9.4 | 137 | Dap 5mg |  |  | |
77/58 | 52.7 ± 9.9 | 135 | Dap 10mg |  |  | |
Weng, et al. (2021) [42] | 93/68 | 55.3 ± 9.5 | 161 | Placebo | 24 | HbA1c,Weight,SBP,DBP,AE, SAE |
103/59 | 54.3 ± 9.5 | 162 | Hen 5mg |  |  | |
101/59 | 54.7 ± 10.7 | 160 | Hen 10mg |  |  | |
Lu, et al. (2021) [43] | 100/51 | 52.4 ± 10.2 | 151 | Placebo | 24 | HbA1c,Weight,SBP,DBP,AE, SAE |
88/62 | 53.3 ± 9.6 | 150 | Hen 5mg |  |  | |
115/36 | 52.2 ± 9.4 | 151 | Hen 10mg |  |  |